3Vilsboll T;Zdravkovic M;Le-Thi T.Liraglutide,a long-acting human glucagon-like peptide-lanalog,givenasmonotherapy,significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2diabetes,2007.
4Nauck M;Frid A;Hermansen K.Efficacy and placebo,all in combination with metformin,In type 2 diabetes:the LEAD (liraglutide effet and action in diabetes)-2study,2009.
5Takamura T,Misu H,Ota T,et al.Fatty liver as a consequence and cause of insulin resistance:lessons from type 2 diabetic liver[J].Endocr J,2012,59:745-763.
6Nadkarni P,Chepurny OG,Holz GG.Regulation of Glucose Homeostasis by GLP-1[J].Prog Mol Biol Transl Sci,2014,121:23-65.
7Cho YM,Wideman RD,Kieffer TJ.Clinical application of glucagon-like peptide 1 receptor agonists for the treatment of type 2 diabetes mellitus[J].Endocrinol Metab(Seoul),2013,28:262-274.
8Mahin DT,Robert T.A simplified method of sample preparation for determination of tritium,carbon-14,or sulfur-35 in blood or tissue by liquid scintillation counting[J].Anal Biochem,1966,16:500-509.
9Vella A,Rizza RA.Application of isotopic techniques using constant specific activity or enrichment to the study of carbohydrate metabolism[J].Diabetes,2009,58:2168-2174.
10Guo Z,Zhou L.Muscle type-dependent responses to insulin in intramyocellular triglyceride turnover in obese rats[J].Obes Res,2005,13:2081-2087.
